|
TADA2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.35530000239848E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.00639999959185E-07 |
| Normal-vs-Stage2 |
4.761500E-02 |
| Normal-vs-Stage3 |
1.04740000006487E-07 |
| Normal-vs-Stage4 |
1.2312999997377E-07 |
| Stage1-vs-Stage2 |
4.561800E-02 |
| Stage1-vs-Stage3 |
5.046200E-02 |
| Stage1-vs-Stage4 |
2.772400E-02 |
| Stage2-vs-Stage3 |
4.017900E-03 |
| Stage2-vs-Stage4 |
1.724170E-03 |
| Stage3-vs-Stage4 |
5.654200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.97239999783139E-08 |
| Normal-vs-AfricanAmerican |
8.520400E-03 |
| Normal-vs-Asian |
1.233460E-04 |
| Caucasian-vs-AfricanAmerican |
5.294400E-01 |
| Caucasian-vs-Asian |
6.543600E-01 |
| AfricanAmerican-vs-Asian |
7.779400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.80399999996739E-06 |
| Normal-vs-Female |
1.51840000017778E-07 |
| Male-vs-Female |
8.581400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.16839999967311E-07 |
| Normal-vs-Age(41-60Yrs) |
2.87519999997432E-06 |
| Normal-vs-Age(61-80Yrs) |
5.84379999946094E-07 |
| Normal-vs-Age(81-100Yrs) |
3.192300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.879000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.956000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.355200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.271200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.556400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.910000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.16790000000722E-05 |
| Classical-VS-Follicular |
2.546600E-01 |
| Classical-VS-Other |
3.982400E-01 |
| Classical-VS-Normal |
1.27849999997931E-06 |
| Tall-VS-Follicular |
2.12729999999883E-05 |
| Tall-VS-Other |
3.536600E-01 |
| Tall-VS-Normal |
4.08910016957975E-10 |
| Follicular-VS-Other |
2.496200E-01 |
| Follicular-VS-Normal |
1.723500E-03 |
| Other-VS-Normal |
1.346110E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.63670000000016E-05 |
| Normal-vs-N1 |
2.99239999446144E-08 |
| N0-vs-N1 |
2.658700E-03 |
|
|
